Results 131 to 140 of about 55,450 (260)

Vaccination and transfusion safety at the time of expanding use of live attenuated vaccines

Vox Sanguinis, EarlyView.
Pierre Tiberghien, Pierre Gallian, Virginie de La Taille, Caroline Bacquet, Syria Laperche   +4 more
wiley   +1 more source

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

A bibliometric analysis of immunotherapy for chronic hepatitis B: trends and hotspots prediction. [PDF]

Front Immunol
Jin X, Tang Y, Ma Y, Li M, Gao Y.
europepmc   +1 more source

The T Cell Receptor: Molecular Sensor, Therapeutic Mediator and Probabilistic Driver of Adaptive Immunity

Immunological Reviews, Volume 340, Issue 1, July 2026.
ABSTRACT Advances in high‐throughput sequencing, single‐cell profiling, and genome engineering have transformed the study of T cell receptors (TCRs), enabling the identification and functional interrogation of antigen‐specific repertoires at an unprecedented scale.
Kilian Schober
wiley   +1 more source

Accuracy of Surveys for Estimating Coverage for Hepatitis A and B Vaccinations in Adults. [PDF]

Prev Chronic Dis
Crane LA, Hurley LP, Daley MF, Beaty B, Rice JD, Homdayjanakul KJ, Lyons J, Black CL, Lu PJ, Singleton JA.   +9 more
europepmc   +1 more source

Herpes Simplex Virus Hepatitis: An Overlooked Cause of Acute Liver Failure Across a Broad Spectrum of Immunocompromise

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background and Aims Herpes simplex virus (HSV) infection is common worldwide, but hepatic involvement is rare. HSV hepatitis is an uncommon yet frequently catastrophic cause of acute hepatitis and acute liver failure (ALF), accounting for < 1% of ALF cases while carrying very high mortality when diagnosis and antiviral therapy are delayed ...
Mario U. Mondelli, Serena Ludovisi, Angela Di Matteo, Gülşen Özkaya Şahin, William Irving, European Society of Clinical Microbiology and Infectious Diseases Study Group for Viral Hepatitis (ESGVH)   +5 more
wiley   +1 more source

Complete genome sequencing and evolutionary analyses of duck hepatitis a viruses in Egyptian duck farms. [PDF]

BMC Vet Res
Yehia N, AbdelSabour MA, Said D, El Naggar RF, Madbouly YM, Mohamed AAE, Salaheldin AH, Rohaim MA.   +7 more
europepmc   +1 more source

Beyond Starch: Towards a Scalable Potato Platform for Molecular Farming

Plant Biotechnology Journal, Volume 24, Issue 7, Page 4619-4639, July 2026.
Re‐engineering potato as a biosafe and host‐optimised platform for plant molecular farming by integrating intrinsic biological traits with targeted engineering strategies. ABSTRACT Thirty‐five years after the first recombinant protein was produced in potato and 30 years after clinical trials of edible vaccines from its tubers, the crop is being ...
Izabela Anna Chincinska, Dorota Sołtys‐Kalina, Audrey Y.‐H. Teh   +2 more
wiley   +1 more source

From legacy to innovation: A comprehensive review of vaccine platforms against viral infections. [PDF]

Virus Res
Farsiu N, Khodadadpour Mahani F, Arefinia N, Charostad J, Pardeshenas M, Mirzaei H, Nakhaie M, Hassandarvish P, AbuBakar S.   +8 more
europepmc   +1 more source

Encapsulin‐Protected Immunotherapeutic Complexes: Bacteria‐Derived Nanoparticles for mRNA Delivery to Eukaryotic Cells

ChemMedChem, Volume 21, Issue 11, 15 June 2026.
Here, we introduce a biological, self‐assembling supramolecular nanoparticle designed to encapsulate eukaryotic‐expressible mRNA within an encapsulin shell via an encapsulin‐RNA adaptor peptide (ERAP). This process occurs in bacteria, and the resulting complex can deliver its mRNA into eukaryotic cells, where it is expressed.
Carlos Francisco Coffeen, Maribel Cayetano‐Cruz, Damaris Ilhuicatzi‐Alvarado, Carmen Méndez, Leticia Moreno‐Fierros, Ismael Bustos‐Jaimes   +5 more
wiley   +1 more source